Adults in British Columbia who are at high risk of severe outcomes from COVID-19 can continue to access the antiviral medication nirmatrelvir-ritonavir (Paxlovid) with full coverage provided by the province.
Paxlovid, approved by Health Canada in January 2022, treats mild to moderate COVID-19 in adults who are at risk of progressing to more severe conditions. While the federal government previously covered the cost, this responsibility has now shifted to BC PharmaCare’s Plan Z, a universal coverage plan. As of May 28, 2024, this plan ensures that B.C. residents with an active medical services plan (MSP) receive full coverage for the medication.
This transition is designed to align coverage with clinical evidence and to improve patient access to appropriate treatments. The medication is particularly recommended for individuals at higher risk of serious illness and hospitalization, including those who are immunocompromised. To be effective, treatment with Paxlovid must begin within five days of the onset of symptoms.
Dr. Bonnie Henry, B.C.’s Provincial Health Officer, emphasized the importance of this coverage: “Ensuring that high-risk individuals have access to effective treatments like Paxlovid is crucial in our ongoing efforts to manage COVID-19 and protect public health.”
The province has also launched a spring COVID-19 booster campaign, available since April 8, 2024. This program aims to extend protection against serious illness from COVID-19, targeting those most at risk of severe outcomes and those who have not yet received an updated vaccine dose. However, any resident who believes they would benefit from an additional dose of the XBB.1.5 COVID-19 vaccine can book an appointment by calling 1 833 838-2323 or visiting a participating pharmacy.
The B.C. government’s commitment to providing full coverage for Paxlovid and promoting booster vaccinations reflects its ongoing efforts to safeguard public health and support those most vulnerable to COVID-19.
